Delayed onset 12 to 72 hours after exposure supports type IV hypersensitivity
Linear streaks with vesicles suggest urushiol exposure
Hands and face are common sites due to frequent exposures
Recurrent dermatitis in same location suggests repeated allergen contact
PITFALLS
Common errors
Assuming antibiotics needed for erythematous pruritic plaques without warmth or tenderness
Using topical antihistamines or topical antibiotics that can worsen allergic dermatitis
Under-treating severe poison ivy with inadequate systemic steroid duration
Missing periocular involvement requiring ophthalmology input for eyelid disease
History
Exposure and timeline
Exposure history
New products
Soaps and shampoos
Cosmetics and sunscreen
Fragrances and essential oils
Topical medications
Occupational and hobby exposures
Gloves and rubber accelerators
Metals and tools
Hair dyes and salon chemicals
Cement and epoxy resins
Plant exposures
Poison ivy, oak, sumac
Gardening and yardwork
Adhesives and medical devices
Tapes and dressings
Continuous glucose monitor adhesives
Wound care products
Clothing and detergents
New detergent or fabric softener
Formaldehyde resins in textiles
Timeline features
Onset relative to exposure
12 to 72 hours after exposure
Worsening with repeated contact
Evolution
Vesiculation to crusting
Persistent pruritus
Prior episodes
Similar rash with same product
Seasonal recurrence with outdoor activities
Symptoms and severity
Symptom profile
Pruritus severity
Sleep disruption
Interference with school or work
Pain or burning
Prominent pain suggests infection or severe drug eruption
Systemic symptoms
Fever
Malaise
Respiratory symptoms
Mucosal symptoms
Oral ulcers
Conjunctival irritation
Risk factors and comorbidities
Predisposing factors
Atopic dermatitis history
Increased barrier disruption risk
Chronic hand wet work
Irritant dermatitis overlap
Immunosuppression
Higher infection risk
Medication reactions
Recent new systemic medication
Relevant coding
Coding anchors
ICD-10 L23.9 allergic contact dermatitis, unspecified cause
ICD-10 L23.7 allergic contact dermatitis due to plants, except food
ICD-10 L23.0 allergic contact dermatitis due to metals
SNOMED CT allergic contact dermatitis concept mapping for problem list
Physical Exam
Distribution and morphology
Morphology assessment
Acute findings
Erythematous papules
Vesicles and bullae
Serous weeping
Subacute findings
Crusting
Scale
Excoriations
Chronic findings
Lichenification
Fissures
Hyperpigmentation
Distribution clues
Sharply demarcated borders matching contact area
Wrist under watchband
Earlobes with earrings
Abdomen under belt buckle
Linear streaks
Plant resin exposure
Eyelid dermatitis
Airborne allergens or transfer from hands
Hand dermatitis pattern
Glove or occupational exposure
Severity and complications
Severity markers
Body surface area estimate
Palmar method
Face and genital involvement
Edema severity
Periorbital swelling
Functional impairment
Hand use limitation
Infection assessment
Honey-colored crusting
Impetigo concern
Purulence
Abscess concern
Warmth and tenderness out of proportion to pruritus
Cellulitis concern
PITFALLS
Exam traps
Bilateral symmetric erythema misread as cellulitis
Vesicles misattributed to herpes without dermatomal pain
Facial swelling assumed allergic contact dermatitis when angioedema features present
Differential Diagnosis
Dangerous and time-sensitive
Must-not-miss conditions
Anaphylaxis
ICD-10 T78.2
Stevens-Johnson syndrome and toxic epidermal necrolysis
ICD-10 L51.1
ICD-10 L51.2
Necrotizing fasciitis
ICD-10 M72.6
Orbital cellulitis
ICD-10 H05.012
Common mimics
Dermatitis and inflammatory
Irritant contact dermatitis
ICD-10 L24.9
Atopic dermatitis flare
ICD-10 L20.9
Seborrheic dermatitis
ICD-10 L21.9
Psoriasis
ICD-10 L40.9
Urticaria
ICD-10 L50.9
Infectious
Cellulitis
ICD-10 L03.90
Impetigo
ICD-10 L01.00
Tinea corporis
ICD-10 B35.4
Scabies
ICD-10 B86
Herpes zoster
ICD-10 B02.9
Differentiating clinical clues
Key discriminators
Contact dermatitis
Pruritus predominant
Exposure distribution
Delayed onset hours to days
Urticaria
Transient wheals less than 24 hours per lesion
Tinea
Annular plaque with peripheral scale
Cellulitis
Tenderness and warmth
Systemic symptoms more likely
Laboratory Tests
Routine testing
Limited role of labs
No routine labs for uncomplicated allergic contact dermatitis
Diagnosis primarily clinical with exposure correlation
If systemic symptoms, targeted labs based on alternate diagnosis
Fever evaluation pathway
Infection or complication workup
Secondary bacterial infection evaluation
Wound culture
Purulent drainage
Failure of initial topical therapy with suspected infection
Complete blood count for systemic toxicity concern
Leukocytosis interpretation with clinical context
C-reactive protein for severe infection concern
Non-specific elevation limitation
Allergy evaluation adjuncts
Allergy testing labs
Total IgE
Not diagnostic for allergic contact dermatitis
Eosinophil count
Non-specific
More relevant for drug reactions and atopy
Diagnostic Tests
Scoring Systems
Severity and tracking tools
Body surface area estimate
Palmar method
Face, hands, genital involvement as high-impact sites
Physician Global Assessment style severity
Mild localized erythema and pruritus
Moderate vesiculation or multiple sites
Severe widespread or facial edema
Patient-reported itch scale
0 to 10 numeric rating for treatment response tracking
MRI
MRI role
Not indicated for allergic contact dermatitis
No benefit for primary diagnosis
If concern for orbital cellulitis complications, MRI orbit as alternative to CT
Specialty-guided choice
CT
CT role
Not indicated for allergic contact dermatitis
No imaging for primary diagnosis
If concern for orbital cellulitis, CT orbit and sinuses
Proptosis
Ophthalmoplegia
Decreased visual acuity
Ultrasound
Ultrasound role
Not indicated for allergic contact dermatitis
No sonographic diagnostic target
If focal fluctuance, point-of-care ultrasound for abscess evaluation
Fluid collection
Guidance for drainage decision
Patch testing and dermatologic diagnostics
Confirmatory and etiologic testing
Patch testing
Persistent or recurrent dermatitis despite avoidance
Occupational dermatitis
Facial or eyelid dermatitis with unclear trigger
Referral to dermatology or contact dermatitis specialist
Skin biopsy
Atypical presentation
Concern for psoriasis, cutaneous T-cell lymphoma, drug eruption
Spongiotic dermatitis pattern supportive but non-specific
KOH preparation
Annular lesions
Tinea mimic concern
Scabies scraping or dermoscopy
Burrows
Household outbreak
Disposition
Level of care
Admission and escalation criteria
Suspected SJS/TEN
Immediate admission
Burn unit or ICU based on institutional pathway
Orbital cellulitis concern
Admission and IV antibiotics pathway
Extensive dermatitis with inability to maintain hydration or oral intake
Consider admission
Severe secondary infection with systemic toxicity
Admission and sepsis pathway
Outpatient management criteria
No systemic toxicity
Afebrile
Hemodynamically stable
Localized or moderate disease with reliable follow-up
Safe discharge with topical therapy plan
Follow-up
Timelines
Primary care follow-up in 3 to 7 days for symptom check
Dermatology follow-up for recurrent or unclear triggers
Patch testing referral if persistent beyond 2 to 4 weeks
Return precautions triggers
Escalation triggers
Rapid spread over hours
Fever or chills
Increasing pain or warmth
Facial swelling affecting vision
Mucosal lesions
Treatment
Allergen avoidance and decontamination
Exposure control
Immediate steps for suspected recent exposure
Soap and water wash within minutes to hours when feasible
Remove contaminated clothing and wash separately
Urushiol exposure measures
Clean under fingernails
Clean tools and pet fur if exposure suspected
Avoid sensitizing topical agents
Topical neomycin avoidance
Topical diphenhydramine avoidance
Skin barrier and non-pharmacologic care
Supportive care
Cool compresses
10 to 15 minutes
Several times daily as needed
Wet dressings for weeping dermatitis
Normal saline or water
Follow with topical corticosteroid and emollient
Emollients
Petrolatum-based ointment
Fragrance-free thick creams
Irritant avoidance
Hot showers avoidance
Harsh soaps avoidance
Topical anti-inflammatory therapy
Topical corticosteroids
Selection by site and severity
Face and intertriginous areas
Hydrocortisone 1% to 2.5% topical
Duration 5 to 7 days then reassess
Trunk and extremities moderate severity
Triamcinolone 0.1% topical
Frequency twice daily
Duration 7 to 14 days then taper frequency
Hands and thick plaques
Clobetasol 0.05% topical
Frequency twice daily
Duration up to 14 days
Avoid face and groin
Application technique
Fingertip unit dosing education
Ointment preferred for dry lichenified lesions
Cream or lotion for weeping areas
Adverse effects counseling
Skin atrophy risk with prolonged high potency use
Perioral dermatitis risk with facial steroids
Topical calcineurin inhibitors
Tacrolimus 0.03% topical for pediatrics
Frequency twice daily
Eyelid and face steroid-sparing option
Tacrolimus 0.1% topical for adults
Frequency twice daily
Pimecrolimus 1% topical
Frequency twice daily
Systemic therapy
Indications for systemic corticosteroids
Extensive involvement
Greater than 20% body surface area
Severe facial or genital involvement
Significant edema impairing function
Severe urushiol dermatitis with progressive vesiculation
Prednisone oral regimen
Initiate 0.5 to 1 mg/kg/day
Typical adult range 40 to 60 mg daily
Duration to prevent rebound for poison ivy
Total course 14 to 21 days
Taper approach
Maintain initial dose 5 to 7 days
Taper by 10 mg every 2 to 3 days as tolerated
Contraindications and precautions
Uncontrolled diabetes
Active infection
Peptic ulcer disease risk
Psychiatric history risk
Alternative systemic options
Intramuscular triamcinolone
Consider when adherence to taper uncertain
Avoid if infection concern
Antipruritic symptom control
Cetirizine 10 mg oral daily
Non-sedating daytime option
Loratadine 10 mg oral daily
Non-sedating daytime option
Hydroxyzine 10 to 25 mg oral at bedtime
Sedation risk
Avoid in high fall risk
Secondary infection management
Bacterial superinfection treatment
Topical mupirocin 2% for localized impetigo
Frequency three times daily
Duration 5 days
Oral antibiotics for cellulitis features
Guided by local antibiogram and risk factors
Avoid antibiotics when dermatitis without infection signs
Evidence and guideline framing
Evidence summary
High potency topical corticosteroids reduce inflammation in localized allergic contact dermatitis
Class I recommendation based on broad dermatology consensus
Systemic corticosteroids for severe urushiol dermatitis require 14 to 21 day course to reduce rebound risk
Class IIa recommendation based on clinical experience and observational evidence
Patch testing for recurrent or occupational dermatitis improves allergen identification and avoidance success
Class I recommendation from specialty society practice standards
ACEP Level C
Antibiotics not indicated for uncomplicated dermatitis without infection signs
Special Populations
Pregnancy
Pregnancy considerations
Diagnosis and testing
Patch testing generally deferred unless essential
Avoid new sensitizers in pregnancy skin care
Topical therapy safety
Low to medium potency topical corticosteroids preferred
Avoid extensive high potency use
Systemic corticosteroids
Use lowest effective dose
Shortest effective duration
Obstetric consultation for prolonged courses
Antihistamines
Cetirizine and loratadine commonly used options
Sedating agents with caution due to maternal drowsiness
Geriatric
Geriatric considerations
Skin fragility
Increased steroid atrophy risk
Prefer lower potency and shorter duration
Medication safety
Sedating antihistamines increase fall risk
Polypharmacy interaction review
Infection risk
Lower threshold for evaluating superinfection
Pediatrics
Pediatric considerations
Weight-based systemic steroid dosing
Prednisone 0.5 to 1 mg/kg/day
Max dosing based on clinical judgment
Topical potency selection
Low potency for face and folds
Medium potency for trunk and extremities
Common pediatric allergens
Nickel
Fragrances
Preservatives in wipes
School and daycare implications
Non-contagious counseling for contact dermatitis
Scabies and impetigo exclusion rules if alternate diagnosis found
Background
Epidemiology
Frequency and patterns
Common clinical problem in primary care and emergency settings
Hand and occupational dermatitis common presentations
Common allergens
Nickel
Fragrance mix
Preservatives
Rubber accelerators
Hair dye agents
Topical antibiotics and anesthetics
Plant dermatitis
Urushiol as common cause of acute vesicular dermatitis in North America
Pathophysiology
Mechanism
Type IV delayed hypersensitivity reaction
T-cell mediated response
Sensitization phase after initial exposures
Elicitation phase after re-exposure
Timing
Symptoms typically begin 12 to 72 hours after exposure
Skin barrier disruption
Increased penetration of allergens and irritants
Therapeutic Considerations
Treatment rationale
Allergen avoidance as definitive intervention
Prevents ongoing immune activation
Topical corticosteroids as first-line for localized disease
Anti-inflammatory effect reduces erythema and vesiculation
Systemic corticosteroids for severe widespread disease
Prevents progression and reduces edema
Adequate duration prevents rebound in urushiol dermatitis
Calcineurin inhibitors for sensitive sites
Steroid-sparing for eyelids and face
Barrier repair with emollients
Reduces recurrence and irritant overlap
Patient Discharge Instructions
Copy discharge instructions
Discharge text
Diagnosis is allergic contact dermatitis
Avoid suspected trigger
Stop the new product or exposure linked to the rash
Do not restart until advised
Skin care
Gentle soap and lukewarm water
Fragrance-free moisturizer at least twice daily
Cool compresses for itch
Medications
Use topical steroid as prescribed
Do not use high potency steroid on face, groin, or armpits unless instructed
If taking prednisone, take in morning with food
Complete the full course as prescribed to prevent rebound
Itch control
Cetirizine or loratadine daily if needed
Sedating antihistamine only at bedtime if prescribed
Return to emergency care now
Trouble breathing
Swelling of lips or tongue
Severe eye swelling or vision change
Fever
Rapidly worsening redness with increasing pain or warmth
Pus or spreading crusting
Mouth sores or rash on eyes or genitals
Follow-up
See primary care in 3 to 7 days if not improving
Dermatology referral if rash keeps coming back or trigger unclear
Patch testing discussion for recurrent cases
References
Clinical guidelines and society resources
Key references
American Contact Dermatitis Society
Patch testing standards and allergen series guidance
American Academy of Dermatology clinical resources
Contact dermatitis management principles
National and regional poison ivy and urushiol dermatitis clinical summaries
Systemic steroid course length to reduce rebound risk
Evidence-based sources
Evidence base
Review literature on allergic contact dermatitis pathophysiology and diagnosis
Type IV hypersensitivity mechanism and timing
Clinical reviews on topical corticosteroid potency selection by body site
Adverse effect risk mitigation
Studies and consensus statements supporting patch testing for recurrent dermatitis
Improved identification and avoidance outcomes
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.